On Oct 02, major Wall Street analysts update their ratings for $ResMed (RMD.US)$, with price targets ranging from $280 to $280.
BofA Securities analyst Lyanne Harrison maintains with a buy rating.
Baird analyst Joseph Vruwink initiates coverage with a buy rating, and sets the target price at $280.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Needham analyst Michael Matson maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $ResMed (RMD.US)$'s main analysts recently are as follows:
The company's investor day presentation revealed an anticipated revenue and earnings outlook until 2030 that surpassed expectations. This outlook is underpinned by artificial intelligence and machine learning, initiatives aimed at generating demand, increased resupply rates, and the company's entry into new markets. There is still an expectation that the return of a competitor will restrain the company's revenue growth, albeit with moderated assumptions.
Here are the latest investment ratings and price targets for $ResMed (RMD.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
